The latest report published by Global Market Insights Inc. suggests that the hemophilia treatment market size may exceed USD 16 billion by 2028. Rising health awareness among people of all income groups, accompanied by the increasing healthcare expenditure and the penetration of several health policies, may transform the market dynamics.

The rapid growth in the number of patients with hemophilia has encouraged government and non-government authorities globally to take necessary initiatives and promote awareness about the disease symptoms, diagnosis, and treatment.

Healthcare authorities have been collaborating with pharmaceutical giants to look for effective treatment and ensure quality care for those living with hemophilia. Such efforts are likely to strengthen the industry forecast.

Some of the fields available in report -

Companies covered in the report | Bayer Healthcare,Biogen, Biotest AG,CSL Behring, Ferring B.V., Genentech, Kedrion, Novo Nordisk, Octapharma, Pfizer, Sanofi SA, Swedish Orphan Biovitrum AB.

Surging number of patients with hemophilia

As per the US Center for Disease Control and Prevention, every 1 in 5,000 male births in the United States is affected by hemophilia A, with over 400 babies being born with the disease each year. Over 1,36,000 people in India have been diagnosed with hemophilia constituting 1 in every 10,000 male births. Out of these, around 19,690 are diagnosed with hemophilia A.

While these statistics are alarming enough to look for opportunities and possible treatment for the affected population, estimations by the WFH are further overwhelming.

The World Federation of Hemophilia, based on 2021 population estimates, claimed that more than 75% of the total 815,000 people living with hemophilia remain undiagnosed and lose a chance to lead a more normal life.

Request for a free sample of this research report @ https://www.gminsights.com/request-sample/detail/2772 

Novel drug launches

In the present scenario, the hemophilia ecosystem has been dealing with a number of challenges, including disease awareness and quality factor availability among several stakeholders, and accessibility to therapy and treatment centers.

However, several organizations are undertaking R&D projects and working towards providing effective patient care and treatment.

For instance, in June 2022, the EMA suggested endowing a conditional marketing authorization for Roctavian (valoctocogene roxaparvovec) in the EU (European Union) for treating adults with acute hemophilia A having no antibodies to adeno-associated virus serotype 5 (AAV5) and lacking factor VIII inhibitors.

Such drug deliveries and treatments will significantly boost the adoption of hemophilia inhibitors, which will stimulate the hemophilia market outlook.

In addition to these factors, factor replacement therapy which is prompt treatment of swollen joints and can be performed at home may fuel the industry landscape due to fewer hospital visits.

As awareness about early disease diagnosis and treatment grows, more and more people will opt for quicker treatment methods. Improving income levels could increase healthcare spending, pushing the adoption of hemophilia treatment in the forthcoming years.

Browse our report store – GMIPulse - https://www.gminsights.com/gmipulse 

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

Contact Us:

Aashit Tiwari

Corporate Sales, USA

Global Market Insights Inc.

Toll Free: +1-888-689-0688

USA: +1-302-846-7766

Europe: +44-742-759-8484

APAC: +65-3129-7718

Email: sales@gminsights.com